In addition, in the IMvigor210 cohort, the patients with UC showing a complete or partial response had a lower EPHB6 expression, directly indicating that anti-EPHB6 immunotherapy may be a novel and reliable therapeutic strategy and could greatly help to promote the response to immunotherapy and improve clinical outcomes for patients with BLCA. The gene discussed is EPHB6; the disease is bladder transitional cell carcinoma.